[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spinal-cord-injury\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spinal-cord-injury":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,132,0,25,[9,43,66,87,123,147,171,192,218,250,272,301,334,358,394,415,440,462,487,514,539,562,582,602,623],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100279862","phase-4-treatment-of-sleep-apnea-in-patients-with-cervical-spinal-cord-injury-100279862",false,"NCT02922894","Treatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury","Inclusion Criteria:\n\n1. healthy adults between the ages of 18 - 89\n2. chronic spinal cord injury patients (T6 and above), \\> 3 months since injury and not on mechanical ventilation, and have not received mechanical ventilation via tracheostomy in the past.\n\nExclusion Criteria:\n\n1. subjects ≤ 17 yrs old\n2. Pregnant and lactating females\n3. History of head trauma that resulted in neurological symptoms or loss of consciousness\n4. advanced heart, lung, metabolic, liver or chronic kidney disease.\n5. severe obstructive or restrictive respiratory defect by PFTs or history of tracheostomy\n6. extreme obesity defined for this protocol as BMI ≥ 40 kg\u002Fm2 (to avoid the effect of morbid obesity on ventilation).",true,"ALL","18 Years","89 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This study will investigate potential therapeutic approaches for sleep-disordered breathing (SDB) in patients with chronic cervical spine injury (\\>6 months post-injury).",[28,29],"Sleep Apnea","Spinal Cord Injury","RECRUITING","2026-06-29",{"date":33,"type":34},"2026-07-01","ACTUAL",{"date":36,"type":34},"2017-06-09",{"date":38,"type":22},"2027-01-30",{"name":40,"class":41},"John D. Dingell VA Medical Center","FED",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":42},"100644900","pilot-study-exploring-the-effects-of-rhythmic-auditory-stimulation-on-gait-in-people-with-motor-incomplete-spinal-cord-injury-100644900","NCT07674927","Pilot Study Exploring the Effects of Rhythmic Auditory Stimulation on Gait in People With Motor Incomplete Spinal Cord Injury","Exploring the Effects of Rhythmic Auditory Stimulation on Gait in Motor Incomplete Spinal Cord Injury: A Pilot Study","Inclusion Criteria:\n\n* Age ≥18 years old\n* Language: English or Spanish only\n* Diagnosis: non-progressive spinal cord lesion; classification as either grade C, D, or E SCI based on American Spinal Injury Association (ASIA) Impairment Scale (AIS)\n* Able to ambulate at least a contact guard assist level\n* Time post injury: ≥6 months\n* Cadence: minimum 40 steps\u002Fminute with clear heel strike\n* Able to consent\n\nExclusion Criteria:\n\n* Individuals who use an assistive device and are unable to achieve a 2-point walking pattern (left-right-left-right) with an assistive device\n* Walks exclusively with a 3-point walking pattern with an assistive device\n* Ambulation requiring a knee-ankle-foot orthosis (KAFO)\n* Presence of additional neurological or medical processes that contribute to weakness\n* Unable to perceive music through the MedRhythyms device",{"count":51,"type":22},15,[53],"NA","This pilot study aims to evaluate the feasibility and preliminary efficacy of a wearable rhythmic auditory stimulation system, MedRhythms, for improving gait parameters in patients with motor incomplete SCI. Up to 15 participants aged 18 years or older with non-progressive SCI will be enrolled. Participants will complete supervised gait training using the MedRhythms device twice weekly during regularly scheduled physical therapy sessions over a six-week period. The device uses shoe-mounted sensors and headphones to deliver real-time individualized rhythmic auditory cues based on the user's gait pattern.\n\nPrimary outcome measures include change in walking speed assessed with the 10-Meter Walk Test. Secondary outcomes include walking endurance measured by the 6-Minute Walk Test, gait parameters obtained through GAITRite analysis, and participant-reported outcomes including the Walking Index for Spinal Cord Injury II (WISCI II) and the SCI Quality of Life Satisfaction with Social Roles and Activities measure. Outcomes will be assessed at baseline, post-intervention (6 weeks), and follow-up (12 weeks).\n\nFindings from this study will provide preliminary data on the feasibility and potential clinical impact of rhythmic auditory stimulation as an adjunctive gait rehabilitation strategy for individuals with incomplete SCI.",[29],"2026-06-23",{"date":58,"type":34},"2026-06-30",{"date":60,"type":22},"2026-06-01",{"date":62,"type":22},"2026-12-31",{"name":64,"class":65},"University of California, Davis","OTHER",{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":42},"100644402","development-of-pain-management-jitai-content-in-multiple-sclerosis-and-spinal-cord-injury-100644402","NCT07663266","Development of Pain Management JITAI Content in Multiple Sclerosis and Spinal Cord Injury","Development of Pain Management Just-In-Time Adaptive Interventions (JITAI) Content in Multiple Sclerosis and Spinal Cord Injury","Inclusion Criteria:\n\n* Able to read and converse fluently in English\n* Multiple sclerosis (MS) or Spinal Cord Injury (SCI) diagnosis\n* Chronic pain ( ≥ 4 on average using a 0-10 NRS for 3-month duration)\n* Access to an internet connected device with a camera and microphone for participating in virtual interview\u002Ffocus group.\n\nExclusion Criteria:\n\n* Cognitive or other impairment (e.g., hearing) that precludes study participation.",{"count":74,"type":22},14,"OBSERVATIONAL","Just-In-Time Adaptive Interventions (JITAIs) offer a framework for delivering personalized behavioral support using time-varying data to optimize the timing and type of intervention content. This project will develop the foundational components of a JITAI tailored to adults with chronic pain and either MS or SCI by drawing on symptom self-management content from existing programs (PainGuide, MyMSToolkit, and MySCIToolkit). Intervention content and delivery parameters will be refined through stakeholder engagement via structured interviews to ensure relevance, acceptability, and feasibility.",[78,29],"Multiple Sclerosis","2026-06-16",{"date":56,"type":34},{"date":82,"type":34},"2026-05-25",{"date":84,"type":22},"2026-07",{"name":86,"class":65},"University of Michigan",{"id":88,"slug":89,"hasResults":12,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":98,"conditions":99,"keywords":104,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100643017","early-phase-1-coupled-gentamicin-lactobacillus-rhamnosus-in-nlutd-100643017","NCT07643974","Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTD","Effect of Dose Timing of Coupled Intravesical Gentamicin and Lactobacillus Rhamnosus LGG on Success and Length of Colonization in Men and Women With SCI\u002FD and NLUTD","Inclusion Criteria:\n\n* Neurologic diagnosis\n* ≥18 years old\n* Neurogenic bladder for at least 6 months\n* No USQNB-IC A, B1, or B2 symptoms\n* No currently diagnosed UTI (within 24 hours of initiating instillations)\n* Community dwelling (not in acute hospital setting)\n\nExclusion Criteria:\n\n* Known genitourinary pathology beyond NLUTD (i.e. kidney stones, bladder stones, vesicoureteral reflux, etc.)\n* Use of prophylactic antibiotics or any antibiotics within 2 weeks of beginning instillations\n* Instillation of intravesical agents other than saline bladder wash\n* Immunodeficiency\n* Psychologic or psychiatric conditions influencing the ability to follow instructions\n* Allergy to ampicillin, daptomycin, gentamicin\u002Fgentamycin, or probiotics\n* Participation in another study which could confound results",{"count":95,"type":22},48,[97],"EARLY_PHASE1","The main objective of the proposed research study is to determine in men and women with spinal cord injury\u002Fdisease and neurogenic bladder whether the dose of coupled gentamicin \\& Lactobacillus rhamnosus GG affects the recolonization of the bladder, and whether the rate of success differs by sex. Secondary objectives include determining whether that recolonization lasts 7, 14, or 28 days; and safety of the coupled gentamicin \\& Lactobacillus instillations.",[29,100,101,78,102,103],"Neurogenic Bladder (NB)","Neurogenic Lower Urinary Tract Dysfunction","Spina Bifida","Urinary Tract Infection(UTI)",[105,106,107,108,109,110,111],"gentamicin","gentamycin","lactobacillus","spinal cord injury","spinal cord disease","urinary tract infection","neurogenic bladder","NOT_YET_RECRUITING","2026-06-08",{"date":115,"type":34},"2026-06-12",{"date":117,"type":22},"2026-06",{"date":119,"type":22},"2027-09",{"name":121,"class":65},"Medstar Health Research Institute",2,{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":133,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":42},"100642753","innovative-brain-computer-interface-for-people-with-spinal-cord-injury-100642753","NCT07640711","Innovative Brain-Computer Interface for People With Spinal Cord Injury","Innovative Neurotechnology For Society - Brain-Computer Interface","INTENSE-BCI","Inclusion Criteria:\n\n* Clinical diagnosis of SCI at the cervical level C4 or higher (C1-C4)\n* Complete or incomplete tetraplegia (quadriplegia) or tetraparesis (quadriparesis), i.e., level A or B at the American Spinal Injury Association (ASIA) Impairment Scale\n* Meeting surgical safety criteria, including surgical clearance by the study physicians\n* Meeting (neuro)psychological evaluation criteria\n* Ability to communicate reliably, via speech or other means\n* Willingness and ability to provide informed consent.\n* Lives within reasonable distance from UMC Utrecht\n* Participant consents to the study and still wishes to participate at the time of the study.\n* Vision and hearing largely intact.\n* For candidates who are not currently receiving invasive ventilation, and who have current respiratory problems (e.g., at night), there should be a clear and confirmed desire to proceed with tracheostomy ventilation whenever that would become necessary.\n\nExclusion Criteria:\n\n* Having a spinal cord injury with a degenerative or progressive etiology.\n* Having evident swallowing problems.\n* Having a significant current or recent anxiety disorder or depression or cognitive impairment that would interfere with obtaining informed consent or fully participating in study activities.\n* Medical conditions contraindicating surgery of a chronically implanted device or that could interfere with study participation (for example active infections, unexplained fever, existing scalp lesions or skin breakdown, osteomyelitis, hepatitis, any autoimmune disease\u002Fdisorder, epilepsy, skin disorders causing excessive skin sloughing or poor wound healing, cranioplasty, significant cardiovascular, metabolic, or renal impairments, chronic oral or intravenous use of steroids or immunosuppressive therapy, active cancer within the past year or requires chemotherapy, uncontrolled autonomic dysreflexia within the past 3 months, hydrocephalus with or without an implanted ventricular shunt or a medical contraindication to stop anti-coagulant medications during surgery, or a catabolic state, or strong and frequent spasms)\n* Presence of pre-surgical findings in anatomical, functional, and\u002For vascular neuroimaging that makes achieving implant locations too challenging or incompatible with desired risk levels.\n* Inability to undergo MRI for pre-implantation evaluation, for example due to the presence of implanted devices that are incompatible with MRI, which may include pacemakers, cardiac defibrillators, spinal cord or vagal nerve stimulators, deep brain stimulators, and cochlear implants or devices that deliver diaphragm pacing.\n* Anticipated need for MRI after implantation of the Brain InterChange system.","70 Years",{"count":42,"type":22},[53],"The goal of this clinical trial is to demonstrate control of digital devices through a brain implant in people with spinal cord injury. The main question it aims to answer is efficient, independent, BCI-based control over digital devices in settings of daily living of an individual with SCI. In this project an advanced generation fully implantable BCI system will be used, the Brain InterChange (BIC) from CorTec.\n\nParticipants will be implanted with an electrode grid on the surface of the brain and an amplifier\u002Ftransmitter on the skull, under the skin. Participation includes visits of researchers for recording and training at home, 1-3 times per week for one year. Extension of participation after one year is possible. If successful, the participant will be able to use the BCI at home independently, without the presence of a researcher.",[29,136,137],"Tetraplegia C1-C4","Quadriplegia","2026-06-05",{"date":140,"type":34},"2026-06-11",{"date":142,"type":22},"2026-08",{"date":144,"type":22},"2028-08",{"name":146,"class":65},"UMC Utrecht",{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":131,"enrollmentInfo":154,"targetDuration":4,"studyType":23,"phases":156,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":42},"100642825","fermented-foods-and-bowel-health-in-sci-100642825","NCT07640152","Fermented Foods and Bowel Health in SCI","High Fermented Food Intake to Improve Gut Microbiome and Bowel Dysfunction in Individuals With SCI","Inclusion Criteria:\n\n* Adults aged 18-70 years\n* At least 1 year post-onset of spinal cord injury, consistent with chronic spinal cord injury\n* Traumatic spinal cord injury involving cervical or thoracic levels\n* American Spinal Injury Association Impairment Scale classification A-D\n* Medically stable, with no recent hospitalizations or acute illnesses\n* Able to safely consume study foods, including fermented and control food products\n* Experiencing neurogenic bowel dysfunction, defined by at least one of the following:\n\n  1. Three or fewer bowel movements per week\n  2. More than 60 minutes required per bowel care routine\n  3. Symptoms of incomplete evacuation\n  4. Abdominal distension\n  5. Fecal incontinence\n* Established and stable bowel program, defined as a consistent individualized routine of timing, frequency, and evacuation methods that has remained unchanged for at least 4 weeks before enrollment\n\nExclusion Criteria:\n\n* Antibiotic use within the past 4 weeks\n* Active gastrointestinal disease, including Crohn's disease, ulcerative colitis, celiac disease, or gastrointestinal obstruction\n* Current intake of probiotics or fermented foods exceeding 3 servings per day\n* Pregnancy or breastfeeding\n* Recent major bowel surgery within the past 12 weeks\n* Unresolved fecal impaction\n* Unstable bowel regimen that could interfere with accurate motility assessment\n* Inability to safely undergo Sitz marker testing, including any of the following:\n\n  1. Inability to swallow the capsule\n  2. Pregnancy, due to radiation exposure\n  3. Contraindication to abdominal X-ray procedures",{"count":155,"type":22},44,[53],"The goal of this clinical trial is to learn whether consuming a high fermented food diet improves bowel function and gut health in adults with chronic spinal cord injury (SCI). The study will also evaluate the feasibility and tolerability of consuming fermented foods daily for 10 weeks. The main questions it aims to answer are:\n\n1. Does a high fermented food diet improve neurogenic bowel dysfunction symptoms and colonic transit in adults with SCI?\n2. Does fermented food intake change gut microbiome composition, short-chain fatty acid production, and intestinal inflammation?\n\nResearchers will compare a high fermented food diet to a control diet to evaluate effects on bowel health and gut microbiome outcomes.\n\nParticipants will:\n\n* Consume study foods daily for 10 weeks\n* Attend 2 in-person study visits\n* Collect stool samples at home and ship them overnight to the research team using provided collection kits and prepaid shipping materials\n* Complete bowel health questionnaires and dietary recalls\n* Undergo Sitz marker testing with abdominal X-rays to assess colonic transit\n* Participate in biweekly monitoring contacts throughout the study period",[29],[160,161,162],"gut microbiome","bowel dysfunction","fermented food",{"date":164,"type":34},"2026-06-10",{"date":166,"type":22},"2026-08-01",{"date":168,"type":22},"2029-07-31",{"name":170,"class":65},"Ohio State University",{"id":172,"slug":173,"hasResults":12,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":180,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":42},"100597752","exoskeleton-training-at-home-to-assist-participants-with-spinal-cord-injuries-to-perform-ambulatory-functions-100597752","NCT07062575","Exoskeleton Training at Home to Assist Participants With Spinal Cord Injuries to Perform Ambulatory Functions.","Clinical Investigation on the Safety and Performance of the ABLE Daily to Assist People With Spinal Cord Injury in Performing Ambulatory Functions in Home and Community Settings","Inclusion Criteria:\n\n* At least 18 years old\n* Chronic SCI (\\>6 months)\n* Injury at levels T1 to L5 (AIS A to D)\n* Walking Index for Spinal Cord Injury (WISCI) score 0 until 9\n* Height between 150-200 cm\n* Weight less than 100 kg\n* Capable of giving informed consent on their own\n* Able to train (at least) 3 days\u002Fweek\n* Able to have at least 1 companion \u002F buddy who can attend a minimum of two of the training sessions, besides the final assessment, and who will learn how to assist them at home and in the community (ideally two companions)\n* Proficiency in walking with the ABLE Exoskeleton\n* At least 8 weeks with minimal use (less than 5 sessions) of wearable robotic exoskeletons for gait assistance at the start of the study.\n\nExclusion Criteria:\n\n* High risk of fractures due to osteoporosis, a dual energy X-ray absorptiometry (DEXA)-scan at the hip, distal femur, and proximal tibia BMD score\n* Fragility fractures of the lower limbs in the last 2 years\n* Deterioration \\>3 in the International Standards for Neurological Classification of SCI (ISNCSCI) score in the last 4 weeks\n* Spinal instability, like spondylolisthesis\n* Disorders of the arms and hands that make walking with crutches impossible\n* Modified Ashworth Scale (MAS) \\>3 in lower limbs\n* Cardiovascular health issues which prevent the participant from training\n* Instability to tolerate 10 minutes of standing without clinical symptoms of orthostatic hypotension\n* Psychological, cognitive issues, or any other condition that does not allow a participant to follow study procedures\n* Medically unstable due to severe comorbidities, including any condition that a physician deems inappropriate for completing study participation\n* Skin problems in areas that would be in contact with the device\n* Height, width, weight, or other anatomical limitations (such as differences in leg length) incompatible with the device\n* Insufficient joint range of motion (ROM) for the device\n* Known pregnancy",{"count":179,"type":22},10,[53],"The goal of this clinical trial is to to confirm the safety and performance of the ABLE Daily to perform ambulatory functions in home and community settings for people with spinal cord injury.\n\nThe experimental period will cover the training period with the ABLE Daily exoskeleton (3 weeks of use at the investigational site with a total of 9 sessions) and the home period (12 weeks of personal use at home and community environments).",[29],{"date":184,"type":34},"2026-06-02",{"date":186,"type":34},"2025-06-19",{"date":188,"type":22},"2026-10-30",{"name":190,"class":191},"ABLE Human Motion S.L.","INDUSTRY",{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":23,"phases":203,"briefSummary":204,"conditions":205,"keywords":206,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":42},"100594696","tele-exercise-to-promote-empowered-movement-in-individuals-with-spinal-cord-injury-100594696","NCT07022808","Tele-Exercise to Promote Empowered Movement in Individuals With Spinal Cord Injury","Tele-Exercise to Promote Empowered Movement in Individuals With Spinal Cord Injury, TEEMS","TEEMS","Inclusion Criteria:\n\n1. at least 12 months post SCI (motor spinal level C5 or below)\n2. between 18-75 years of age\n3. ability to elevate shoulders \\>25% range\n4. use assistive technology for mobility\n5. not currently receiving structured rehabilitation (i.e. new episode of inpatient or outpatient rehabilitation services to treat a new or exacerbated mobility issue. Individuals attending outpatient services for ongoing wellness reasons are eligible to participate).\n6. screened and medically cleared (if appropriate) for participation using the American College of Sports Medicine (ACSM) Preparticipation Health Screening Tool. The ACSM Health Screen helps to determine if an individuals should seek a medical referral prior to participation in exercise. The guideline for the screening are based on (1) current exercise participation, (2) history and symptoms of cardiovascular, metabolic, or renal disease, and (3) desired exercise intensity. The algorithm is based on risk stratification and minimizing the barriers of exercise participation by decreasing the number of unnecessary medical referrals.\n\n   For this study and the safety of participants, those who need a medical referral based on the ACSM preparticipation health screen will be required to provide documentation of medical clearance from their primary medical provider prior to study participation. Dr. York will review screening information and medical clearances to ensure safe inclusion.\n7. internet access to attend synchronous exercise classes\n\nExclusion Criteria:\n\n1. Known or suggestive cardiovascular, metabolic, and\u002For renal disease and\u002For presence of absolute or relative contraindications to exercise participation that is considered unsafe by their medical team\n2. self-report previous hospitalization within a month,\n3. self report active pressure injury\n4. self report recent osteoporotic fracture\n5. self-report uncorrectable vision loss,\n6. self-report preexisting neurological conditions other than SCI","75 Years",{"count":202,"type":22},200,[53],"To achieve our specific aims and hypotheses we will conduct a parallel group mixed methods randomized control trial comparing participation in the TEEMS program with exercise via asynchronous video library equivalent (control). The use of mixed methods will allow for the integration of quantitative findings with the qualitative, lived perspective of participants to provide a comprehensive analysis of the tele-exercise program outcomes. All aspects of the study from recruitment, screening, data collection, tele-exercise delivery and team meetings will be virtual to promote access and inclusion by removing barriers and promoting engagement. This study will compare our live group TEEMS program with individual pre-recorded exercise videos. We created TEEMS with the intention of maximizing exercise independence for participants, which decreases need for caregivers during physical activity. The design and participation in TEEMS is meant to increase personal factors that facilitate participation in exercise. These personal factors include confidence and positive associations with exercise. When these personal factors are targeted, individuals with SCI are more likely to participate in physical activity, which supports overall health and QoL.",[29],[207,108,208,209],"randomized control trial","physical activity","tele-exercise",{"date":211,"type":34},"2026-06-03",{"date":213,"type":34},"2026-05-04",{"date":215,"type":22},"2029-08-31",{"name":217,"class":65},"Drexel University",{"id":219,"slug":220,"hasResults":12,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":12,"sex":17,"minAge":225,"maxAge":200,"enrollmentInfo":226,"targetDuration":4,"studyType":23,"phases":228,"briefSummary":231,"conditions":232,"keywords":236,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":249},"100638318","phase-2-pilot-study-of-galantamine-to-treat-metabolic-syndrome-in-people-with-chronic-traumatic-spinal-cord-injury-sci-100638318","NCT07625332","Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)","Pilot Study of Tolerability and Preliminary Efficacy of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)","Inclusion Criteria:\n\n* Adults aged 21-75 years (male or female)\n* Chronic (≥1 year post injury) traumatic non-progressive spinal cord injury (SCI)\n* Wheelchair user for community mobility\n* Injury level of tetraplegia (cervical level) or paraplegia (all levels)\n* SCI-specific obesity indicated by waist circumference ≥94 cm\n* Resting heart rate \\>45 bpm based on 10 measurements over 10 minutes\n* Without clinically significant cardiovascular abnormalities as indicated by 12-lead ECG\n* Tolerable bowel routine indicated by a score of \\\u003C10 on the International SCI Bowel Function Data Set (ISCI-BDS)\n* Metabolic Syndrome (MetS) defined by the presence of at least three of the following: (1) obesity indicated by SCI-specific waist circumference ≥94 cm, (2) elevated fasting glucose ≥100 mg\u002FdL, (3) dyslipidemia: high triglycerides ≥150 mg\u002FdL or low HDL cholesterol \\\u003C40 mg\u002FdL for men and \\\u003C50 mg\u002FdL for women, (4) C-reactive protein (CRP) levels \\>1 mg\u002FdL\n* Able to understand and communicate in English at the level of describing adverse event frequency and severity and completing validated outcome measures\n* Willingness to comply with all study procedures and availability for the duration of the study\n* Provision of signed and dated informed consent form\n\nExclusion Criteria:\n\n* Diagnosis of neurological injury or condition other than SCI\n* Progressive condition that would be expected to change neurological status\n* Signs and symptoms of cardiovascular disease or cardiac arrhythmias\n* Resting heart rate \\\u003C45 bpm\n* Score of 10 or greater on the ISCI-BDS v2.1 indicating moderate to severe neurogenic bowel dysfunction\n* Severe concurrent medical disease, condition, or illness judged to be contraindicated by the site physician\n* Psychopathology documented in the medical record or history that may conflict with study objectives\n* Pregnancy (participant reported or determined by clinical lab test), women who plan to become pregnant, or women who are nursing during the study\n* Active cancer or currently in treatment for cancer\n* Triglyceride levels ≥400 mg\u002FdL\n* Chronic use of medications with known or probable interactions with galantamine\n* Enrolled in another research study that is likely to interfere with conduct or results of the current study\n* Any other reason the site physician feels that participation is contraindicated","21 Years",{"count":227,"type":22},60,[229,230],"PHASE2","PHASE3","The purpose of this research study is to measure the tolerability and preliminary efficacy of a drug, galantamine, to treat metabolic syndrome (MetS) by reducing circulating inflammation in people with spinal cord injury (SCI). Galantamine is FDA-approved for the treatment of Alzheimer's disease. Here, the drug is considered experimental for the purposes of this study.",[29,233,234,235],"Traumatic Spinal Cord Injury","Paraplegia and Tetraplegia","Metabolic Syndrome",[108,237,238,239],"tetraplegia","paraplegia","metabolic syndrome","2026-05-28",{"date":242,"type":34},"2026-06-04",{"date":244,"type":22},"2026-06-15",{"date":246,"type":22},"2027-12",{"name":248,"class":65},"Northwell Health",3,{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":12,"sex":17,"minAge":258,"maxAge":4,"enrollmentInfo":259,"targetDuration":261,"studyType":75,"phases":4,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":42},"100572494","cohorte-coscinus---biocollection-100572494","NCT06734000","Cohorte COSCINUS - Biocollection","Cohorte COSCINUS - Biocollection COhort in Spinal Cord Injury - Nantes Follow-Up Standardization","COSCINUS","Inclusion Criteria:\n\n* All individuals with spinal cord injury admitted to the neurological PRM department of the Nantes University Hospital at the initial phase of development of the paraplegia or tetraplegia could participate, regardless the clinical neurological status.\n\nExclusion Criteria:\n\n* Patients not covered by social security.","16 Years",{"count":260,"type":22},105,"5 Years","COSCINUS is a standardized framework for evaluating temporal trends in SCI causes, SCI characteristics, and demographic patterns. It allows a precise estimation of medical complications' incidence, their evolution over time, as well risk factors influencing these complications, including management modalities. Moreover, COSCINUS provides a high-quality research platform, including clinical, epidemiological, biostatistical, and IT expertise, thereby promoting fundamental research in spinal cord injury and related autonomic dysfunctions. As a national epidemiological tool, COSCINUS offers unique analytical perspectives, promising significant contributions to the understanding and management of spinal cord injuries.",[29],{"date":265,"type":34},"2026-05-29",{"date":267,"type":34},"2024-12-13",{"date":269,"type":22},"2032-10-10",{"name":271,"class":65},"Nantes University Hospital",{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":200,"enrollmentInfo":280,"targetDuration":4,"studyType":23,"phases":282,"briefSummary":283,"conditions":284,"keywords":285,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":295,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":299,"locationsCount":42},"100289902","deep-brain-stimulation-in-patients-with-incomplete-spinal-cord-injury-for-improvement-of-gait-100289902","NCT03053791","Deep Brain Stimulation in Patients With Incomplete Spinal Cord Injury for Improvement of Gait","A Phase I\u002FII Open-label Multicenter Trial to Evaluate Safety and Preliminary Efficacy of Unilateral Deep Brain Stimulation of the Mesencephalic Locomotor Region in Patients With Incomplete Spinal Cord Injury","DBS-SCI","Inclusion Criteria:\n\n1. Informed Consent\n2. Participation in two assessment sessions before enrollment (Screening and baseline)\n3. Willingness and ability to comply with the protocol and to attend required study training and visits\n4. Male or female subjects\n5. Age 18-75\n6. Motor incomplete SCI\n7. Level of lesion: T10 and above, based on AIS level, preservation of sacral function\n8. Focal spinal cord disorder caused by either trauma or non-traumatic and non-progressive condition (like hemorrhage, benign tumor)\n9. Minimum 3 months of recovery after SCI\n10. Completed in-patient rehabilitation program\n11. WISCI II, level \\>2 (0-20 items): assistance of one or more persons. Ability to walk at least 10 meters\n12. Stable medical and physical condition.\n13. Adequate care-giver support and access to appropriate medical care in patient's home community\n\nExclusion Criteria:\n\n1. Enrollment of the investigator, his\u002Fher family members, employees and other dependent persons\n2. Limitation of standing and walking function based on accompanying (CNS) disorders\n3. Cardiovascular disorders restricting physical training or peripheral nerve disorders\n4. Implanted technical devices (pacemaker, defibrillator)\n5. History of significant autonomic dysreflexia\n6. Cognitive disorders\u002Fbrain damage\n7. Drug refractory epilepsy\n8. Severe joint contractures disabling or restricting lower limb movements\n9. Haematological disorders with increased risk of bleeding during surgical interventions\n10. Participation in another study with investigational drug within the 30 days preceding and during the present study\n11. Congenital or acquired lower limb abnormalities (affection of joints and bone)\n12. Women who are pregnant or breast feeding or planning a pregnancy during the course of the study\n13. Lack of safe contraception\n14. Inability of the participant to follow the procedures of the study, e.g. due to language problems, psychological problems, dementia etc.\n15. Known or suspected non-compliance, drug or alcohol abuse\n16. Current or prior malignancy",{"count":281,"type":22},5,[53],"Spinal cord injuries are anatomically mostly incomplete, showing tissue bridges of the spinal cord at the injury site. Of the 60% functionally incomplete patients, about half face a life in the wheelchair. Besides conventional rehabilitation, no prominsing further treatment options exist. One of the most plastic systems involved in locomotion is the pontomedullary reticulospinal tract, which is the oldest locomotor command system existing in most vertebrates, including primates. Muscle activation patterns for limb movements are programmed in the spinal cord and have to be activated and coordinated through commands from the so called mesencephalic locomotor region (MLR). The MLR consists of nerve cells in the lower mesencephalic tegmentum sending uni- and bilateral signals through the medullary reticulospinal tracts. Classical physiological studies showed that electrical stimulation of the MLR induce locomotion. For the first time this approach was transferred and recently published in a model of induced incomplete spinal cord injury by the Schwab group. Rats severly impaired in motor hindlimb control with only 10-20% spared white matter, recovered with fully functional weight bearing locomotion under MLR deep brain stimulation (DBS). Even rats with only 2-10% spared white matter regained weight supporting stepping. DBS is a clinical standard treatment option in patients with movement disorders but does not relieve all symptoms. Therefore, small studies of MLR stimulations have been safely used in Parkinsonian patients showing freezing of gait and frequent falls with variable results. In a translational approach, we aim at performing a multidisciplinary phase one clinical trial with 5 patients and incomplete spinal cord injury. With the means of our established universitary setup for DBS treatments the operations will be performed unilaterally under local anaesthesia in the Division of Neurosurgery, USZ, with perioperative electrophysiological recordings, clinical assessments and gait analysis under test stimulation in the Spinal Cord Injury Center Balgrist.",[29],[286,287,288,289,290,291,292,293,294],"Deep brain stimulation","DBS","Spinal cord injury","SCI","Paraplegia","Mesencephalic locomotor region","MLR","Pedunculopontine nucleus","PPN",{"date":265,"type":34},{"date":297,"type":34},"2018-03-15",{"date":246,"type":22},{"name":300,"class":65},"University of Zurich",{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":131,"enrollmentInfo":307,"targetDuration":309,"studyType":75,"phases":4,"briefSummary":310,"conditions":311,"keywords":319,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":333},"100488290","nerve-transfer-surgery-to-restore-upper-limb-function-after-cervical-spinal-cord-injury-100488290","NCT05638191","Nerve Transfer Surgery to Restore Upper-limb Function After Cervical Spinal Cord Injury","Inclusion Criteria:\n\n* Traumatic, motor-complete cervical SCI (AIS A or B)\n* Male or female, ages 18-70\n* Consent and plan to undergo nerve transfer to restore grasp function in at least one limb\n* Motor grade 4-5 at C5\n* Motor grade 0-1 at C8\u002FT1\n* Injury duration within 6 months at the time of surgery\n* English-speaking and cognitively intact\n* Able to provide informed written consent\n* Able to attend and comply with the testing protocols\n\nExclusion Criteria:\n\n* Inability or unwillingness to participate in post-operative rehabilitation (in person or virtual)\n* Secondary complication of SCI (e.g., intractable neuropathic pain, edema, contracture) or major medical comorbidity (e.g., traumatic brain injury) that would independently influence response to surgery or ability to participate in rehabilitation",{"count":308,"type":22},40,"2 Years","The goal of this prospective, open-label cohort study is to assess functional outcomes in individuals with cervical spinal cord injury who have undergone nerve transfer surgery to restore upper limb function. The main questions it aims to answer are:\n\n* Does nerve transfer improve hand function in individuals with cervical spinal cord injury?\n* What factors are associated with functional improvement following nerve transfer? Researchers will compare functional outcomes at 24 months post-surgery to 1) baseline outcomes and 2) individuals with cervical spinal cord injury who did not undergo nerve transfer.\n\nParticipants who have received nerve transfer surgery as part of their regular medical care will complete functional hand tests, electrodiagnostic assessments, and questionnaires on independence and mood every 3 months for 24 months after surgery.",[29,312,313,314,315,316,317,318],"Spinal Cord Injury at C5-C7 Level","SCI - Spinal Cord Injury","Upper Extremity Paralysis","Upper Extremity Dysfunction","Tetraplegia","Upper Extremity Paresis","Cervical Spinal Cord Injury",[108,320,321,289,322,323,324],"upper extremity nerve transfer","nerve transfer","nerve reconstruction","quadriplegia","paresis","2026-05-27",{"date":265,"type":34},{"date":328,"type":34},"2021-06-03",{"date":330,"type":22},"2028-01",{"name":332,"class":65},"University of British Columbia",4,{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":343,"conditions":344,"keywords":347,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":354,"completionDateStruct":355,"leadSponsor":357,"locationsCount":42},"100628879","goat-gait-observation-of-achilles-tendon-100628879","NCT07467382","GOAT (Gait Observation of Achilles Tendon)","Characterization of Mechanical Properties of Achilles Tendon During Gait in Spastic Paresis Syndrome","GOAT","Inclusion Criteria:\n\nStudy population:\n\n• Cognitive abilities compatible with the experiment: no language or judgement disorders preventing understanding of the research or expression of consent. An aphasia severity score greater than or equal to 3 on the Boston Diagnostic Aphasia Examination (BDAE) scale will be required for inclusion.\n\nPost-stroke population:\n\n* Adult male or female\n* Patient who has had a stroke \\> 7 days ago\n* Patient hospitalised (in conventional hospitalisation or day hospital) in the neurological physical and medical rehabilitation department of Nantes University Hospital\n* Patients with voluntary motor function rated between 2 and 4 on the MRC (Medical Research Council) scale at the GM level\n* Patients classified as 3 to 8 on the New Functional Ambulation Classification\n* Indication to perform a quantified gait analysis as part of clinical management\n\nPost-spinal cord injury population:\n\n* Adult men or women\n* Patients with incomplete spinal cord injury graded ASIA AIS C or D from C2 to L5\n* Patients hospitalised (in conventional hospitalisation or day hospital) in the neurological physical and occupational therapy department of Nantes University Hospital\n* Patients with voluntary motor function rated between 2 and 4 on the MRC (Medical Research Council) scale at GM level\n* Patients rated 13-20 on the WISCI-II scale\n* Indication for a quantified gait analysis as part of clinical care\n\nHealthy population:\n\n• Adult men or women with no nervous system disorders.\n\nExclusion Criteria:\n\nPost-stroke and post-spinal cord injury population:\n\n* Minors;\n* History of calf surgery, surgery to reduce triceps surae spasticity, or intramuscular injection (e.g. botulinum toxin) in the plantar flexors \\\u003C 6 months;\n* Patients with a progressive condition that contraindicates exertion (syrinx, cardiovascular instability);\n* Peripheral pathology of the lower limb in question.\n\nHealthy population:\n\n* History of calf surgery;\n* History of muscle injury, fracture or sprain of the lower limb \\\u003C 3 months;\n* History of neurological condition.",{"count":227,"type":22},"The purpose of this study is to evaluate the mechanical properties of the Achilles tendon (stiffness, length, volume) and the force production capacities of the gastrocnemius medialis muscle in patients with spastic paresis (post-stroke or incomplete spinal cord injury) compared to healthy subjects, during gait.",[345,346,29],"Spastic Paresis","Stroke",[348,349,350,351],"Achilles tendon","Gait analysis","Ultrasound","Muscle-tendon interaction","2026-05-22",{"date":325,"type":34},{"date":60,"type":22},{"date":356,"type":22},"2027-12-01",{"name":271,"class":65},{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":12,"sex":17,"minAge":366,"maxAge":131,"enrollmentInfo":367,"targetDuration":4,"studyType":23,"phases":369,"briefSummary":370,"conditions":371,"keywords":375,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":122},"100201147","cortical-recording-and-stimulating-array-brain-machine-interface-100201147","NCT01894802","Cortical Recording and Stimulating Array Brain-Machine Interface","A Sensorimotor Microelectrode Brain-Machine Interface for Individuals With Significant Upper Limb Impairment","CRS-BMI","Inclusion Criteria:\n\n1. Subjects must have limited or no ability to use one or both hands due to cervical spinal cord injury, brainstem stroke, brachial plexus injury, above-elbow amputation, or spinal stroke. Individuals with intact limbs must have less than grade 2 strength in finger flexor and abduction on the contralateral side to the implant and a t-score \\\u003C35 on the PROMIS Upper Extremity Short Form. The non-functional hand(s) may be involved passively in functional tasks; for example, pushing an object or passively grasping an object placed into the hand. However, the participant must report that they have no functional use of their hand(s).\n2. Subjects must report that they are unable to perform functional activities with the hand contralateral to implantation.\n3. Subjects must be over 1 year post-injury at time of implantation. In addition, subject must report no worsening in neurologic status (strength, sensation) for the previous 6 months.\n4. Subjects must be between the ages of 22-70 years old at the time of enrollment and completion of the study. Participants outside this age range may be at an increased surgical risk and increased risk of fatigue during BMI training.\n5. Subjects must live within 2 hours of the research site during the study or be willing to travel to the research site at least once per week for BMI training.\n6. If subjects do not live in the area, they are expected to stay somewhere within 2 hours of the research site for at least 18 months after enrollment.\n7. Subjects must be able to communicate with the investigators in English because of the need to follow the instructions of the study team.\n8. Subjects must show an understanding of the study goals and have the ability to follow simple directions as judged by the investigators\n9. Subjects must have results that are within normal limits on neuropsychological and psychosocial assessment; psychosocial health and support will be assessed by interview with the psychologist.\n10. Subjects must be able to activate distinct cortical areas during imagined or attempted movement tasks (i.e. hand movement and speaking or moving the mouth); this will be evaluated with functional magnetic resonance imaging (fMRI) as part of screening.\n11. Subjects must have a stable psychosocial support and caregivers who are able to perform the necessary daily care of the participant's skin and pedestal site. This requires that the subject identify a caregiver and a backup who have been in place for greater than 6 months and are able to provide needed physical and psychosocial support. This will be assessed by the sponsor-investigator and study neurosurgeon.\n12. Subjects must have a life expectancy greater than 18 months as assessed by the study investigator and neurosurgeon sub-investigator\n13. Documentation of informed consent must be obtained from the participant or their legal representative.\n14. Participants with transhumeral amputation must have been evaluated for a prosthesis, and if deemed appropriate, were fit with an optimized prosthesis. The prosthesis should be used\u002Fconsidered for the PROMIS evaluation.\n\nExclusion Criteria:\n\n1. Visual impairment such that extended viewing of a computer monitor would be difficult even with ordinary corrective lenses\n2. Another serious disease(s) or disorder(s) that could affect ability to participate in this study (verified during pre-op anesthesia evaluation to determine surgical risk status)\n3. Recent history of pressure sores that could be exacerbated by 1-2 days of bed rest\n4. Metallic implant(s) that would prohibit the subject from having an fMRI scan; spinal fixators are generally non-ferrous and would not exclude someone from participating in the study\n5. Any type of implantable generator such as a pacemaker, spinal cord stimulator, cochlear implant, deep brain stimulator (DBS), DBS leads, vagus nerve stimulator, or defibrillator\n6. Women of childbearing age who are pregnant, lactating, or plan to become pregnant during the next 25 months\n7. Allergy to contrast medium or kidney failure that could be exacerbated by contrast agent (for MRI)\n8. Subjects receiving medications (such as sedatives) chronically that may retard motor coordination and cognitive ability\n9. Individuals who require routine MRI, therapeutic ultrasound, or diathermy\n10. Individuals with osteomyelitis\n11. Severe skin disorder that causes excessive skin sloughing, lesions or breakdown of the scalp\n12. History of myocardial infarction or cardiac arrest or with intractable cardiac arrhythmias\n13. Individuals with an implanted hydrocephalus shunt\n14. Individuals who have had a stroke caused by a surgical procedure\n15. Active infection(s) or unexplained fever (verified during pre-op anesthesia evaluation to determine surgical risk status)\n16. Consumption of more than 1 alcoholic beverage per day on average\n17. Receiving chronic oral or intravenous steroids or immunosuppressive therapy\n18. Active cancer within the past year (other than adequately treated basal cell or squamous cell skin cancer) or require chemotherapy\n19. Uncontrolled insulin dependent diabetes mellitus\n20. Uncontrolled autonomic dysreflexia within the past 3 months (for those with spinal cord injury)\n21. Individuals with seizure disorders currently being treated with anti-epileptic medications and individuals with a familial history of seizure disorders\n22. Individuals who have attempted suicide in the past 12 months\n23. Individuals who are immunosuppressed or who have conditions that typically result in immunocompromise (including, but not limited to: ataxia-telangiectasia, cancer, Chediak-Higashi syndrome, combined immunodeficiency disease, complement deficiencies, DiGeorge syndrome, HIV\u002FAIDS, hypogammaglobulinemia, Job syndrome, leukocyte adhesion defects, malnutrition, panhypogammaglobulinemia, Bruton disease, congenital agammaglobulinemia, selective deficiency of IgA and Wiscott-Aldrich syndrome)\n24. Individuals who have had previous neurosurgical intervention involving the frontal lobes (especially the motor cortex) and\u002For parietal lobe (especially the somatosensory cortex) that is likely to impact the viability of an intracortical electrode\n25. Individuals with active psychiatric concerns, including but not limited to major depression, bipolar disorder, schizophrenia or other psychotic disorder and post-traumatic stress disorder\n26. Individuals with substance abuse within 6 months of study participation\n27. Individuals who are judged by a clinician as being an unsafe ambulator - This would be decided based on a history of frequent uncontrolled falls more than 3 or 4 in a year, or falls that resulted in injury\n28. Individuals who plan to participate in contact sports or sports that require a helmet","22 Years",{"count":368,"type":22},30,[53],"The purpose of this research study is to demonstrate the safety and efficacy of using two CRS Arrays (microelectrodes) for long-term recording of brain motor cortex activity and microstimulation of brain sensory cortex.",[316,29,372,373,374],"Brainstem Stroke","Brachial Plexus Injury","Above Elbow Amputation",[316,137,288,376,377,378,379,380,381,382,383,384],"Brainstem or spinal stroke","Neuroprosthetic","Brain-machine interface","Brain-computer interface","Neural activity","Sensory stimulation","Microstimulation","Brachial plexus injury","Above elbow amputation","2026-05-18",{"date":387,"type":34},"2026-05-20",{"date":389,"type":34},"2013-12-01",{"date":391,"type":22},"2029-12",{"name":393,"class":65},"Michael Boninger",{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":401,"enrollmentInfo":402,"targetDuration":4,"studyType":23,"phases":404,"briefSummary":405,"conditions":406,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":42},"100639160","implantable-wireless-brain-machine-interface-system-for-spinal-cord-injury-efficacy-and-safety-study-100639160","NCT07603752","Implantable Wireless Brain-Machine Interface System for Spinal Cord Injury: Efficacy and Safety Study","A Prospective, Open-label, Multi-center, Single-arm Study to Evaluate the Efficacy and Safety of an Implantable Wireless Brain-machine Interface System in Patients With Spinal Cord Injury","Inclusion Criteria:\n\n1. Aged 18 to 65 years old (inclusive), with no restriction on gender.\n2. Meeting all the following requirements:\n\n(1) Suffering from complete or incomplete tetraplegia secondary to cervical spinal cord injury (C2-C6); (2) Diagnosed in line with the 2019 revised International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) issued by the American Spinal Injury Association (ASIA), with neurological injury grade classified as Grade A to Grade C; (3) Having fulfilled the above diagnostic criteria for no less than 12 months; 3. Confirmed by imaging examinations and neurological evaluations that the motor-related cerebral cortex is structurally intact, functionally normal and free of obvious atrophy, organic lesions or functional disorders; 4. Fertile participants must agree to use effective contraception throughout the trial period; 5. Participants, either independently or with caregiver assistance, are willing to follow investigators' guidance, comply with all procedures stipulated in the study protocol and complete all scheduled trial visits as required; 6. Having normal cognitive function with a Mini-Mental State Examination (MMSE) score ≥20 points (excluding three-step commands, writing and drawing items); 7. Elbow flexor muscle strength ≤ Grade 3 assessed by ISNCSCI scale; 8. Being of good compliance, voluntarily participating in the clinical trial and signing the informed consent form.\n\nExclusion Criteria:\n\n1. Having received implantation of any metallic objects or devices in the body (e.g., pacemaker, defibrillator, neurostimulator, cochlear implant, electronic devices, drug infusion pumps, etc.), excluding dental metallic implants or other implants confirmed to have no impact on the study.\n2. Long-term use of anticoagulants or antiplatelet drugs prior to screening, with antiplatelet drugs not discontinued for at least 2 weeks before surgery; or suffering from hematological diseases such as aplastic anemia and systemic lupus erythematosus; or having clinically significant abnormal coagulation function during the screening period.\n3. Having contraindications to magnetic resonance imaging (MRI) or being unable to complete MRI examinations for other reasons.\n4. Being assessed by anesthesiologists as intolerant to anesthetic surgery.\n5. Having neurological diseases (e.g., cerebrovascular lesions, intracranial infection, neurodegenerative diseases, epilepsy) or a history of craniocerebral trauma leading to severe brain dysfunction or obvious abnormal electroencephalographic signals, as judged by investigators.\n6. Suffering from physical or pathological conditions that may cause failed normal healing of scalp wounds.\n7. Being in the stage of acute infection or suffering from other severe infections.\n8. Having any unstable or severe medical conditions that may interfere with study procedures or confound the evaluation of study endpoints, including previously diagnosed mania, depression, Alzheimer's disease, mood disorders, intellectual disability, other cognitive disorders, severe attention deficit, etc.\n9. Suffering from severe dysfunction of vital organs including heart, lung, liver and kidney: such as severe cardiovascular diseases (e.g., hospitalization or cardiac surgery due to myocardial infarction within 3 months, congestive heart failure, myocardial infarction, severe unstable arrhythmia, hypertrophic cardiomyopathy, severe aortic stenosis, aneurysm); severe pulmonary diseases (moderate to severe pneumonia, respiratory failure, etc.).\n10. Diagnosed with malignant tumors, autoimmune diseases, peripheral neuropathy, poorly controlled diabetes mellitus, or other severe diseases deemed unsuitable for this clinical trial by investigators.\n11. Severe spasticity, severe neuralgia, or uncontrolled complex regional pain syndrome that hinders participants from completing training sessions.\n12. Spinal cord dysfunction or injury caused by autoimmune disorders.\n13. Having visual impairment that makes it difficult to view display screens for a long time even with standard corrective lenses.\n14. Suffering from infectious diseases such as active pulmonary tuberculosis, viral hepatitis (hepatitis B, hepatitis C), syphilis and AIDS.\n15. Receiving pharmacotherapy or physical therapy affecting the central nervous system before enrollment, and unable to discontinue such treatments after enrollment as assessed by investigators.\n16. Having a history of drug abuse, nicotine dependence or alcohol dependence.\n17. Pregnant or lactating females, or those planning to become pregnant during the study period.\n18. Having participated or currently participating in any drug clinical trial within 90 days prior to enrollment, or any other medical device clinical trial within 30 days prior to enrollment.\n19. Any other conditions deemed inappropriate for participation in this clinical trial by investigators.","65 Years",{"count":403,"type":22},34,[53],"This is a prospective, open-label, multi-center, single-arm study to evaluate the efficacy and safety of an implantable wireless brain-machine interface (BMI) system in patients with spinal cord injury. Eligible participants will undergo screening after signing informed consent, followed by BMI system implantation. Follow-up visits will be conducted postoperatively to assess brain-control performance and safety.",[29],"2026-05-16",{"date":352,"type":34},{"date":410,"type":34},"2026-04-28",{"date":412,"type":22},"2027-06-30",{"name":414,"class":191},"Shanghai StairMed Technology Co., Ltd.",{"id":416,"slug":417,"hasResults":12,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":401,"enrollmentInfo":423,"targetDuration":4,"studyType":23,"phases":424,"briefSummary":425,"conditions":426,"keywords":429,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":4},"100640039","effects-of-functional-electrical-stimulation-on-spasticity-quadriceps-muscle-strength-and-functional-mobility-in-individuals-with-paraplegia-100640039","NCT07583576","Effects of Functional Electrical Stimulation on Spasticity, Quadriceps Muscle Strength and Functional Mobility in Individuals With Paraplegia","Effects of Functional Electrical Stimulation on Spasticity, Quadriceps Muscle Strength and Functional Mobility in Individuals With Paraplegia: A Randomized Controlled Trial","FES-PAR-RCT","Inclusion Criteria:\n\n* Participants will be included in the study if they meet all of the following criteria:\n* Aged between 18 and 65 years\n* Diagnosed with spinal cord injury resulting in paraplegia (traumatic or non-traumatic etiology)\n* Classified as ASIA Impairment Scale C or D\n* Medically stable condition\n* Presence of lower extremity spasticity (Modified Ashworth Scale ≥ 1)\n* Ability to understand and follow simple instructions\n* Willingness to participate and provide informed consent\n\nExclusion Criteria:\n\n* Participants will be excluded if they present any of the following conditions:\n* Presence of cardiac pacemaker or implanted electrical device\n* Severe cognitive impairment or communication difficulties preventing participation\n* Active infection or systemic inflammatory condition\n* Severe lower extremity contractures or deformities limiting movement\n* Dermatological conditions or open wounds preventing FES application\n* History of severe autonomic dysreflexia triggered by electrical stimulation\n* Uncontrolled medical conditions that may interfere with participation or safety",{"count":308,"type":22},[53],"Spinal cord injury (SCI)-related paraplegia is a complex neurological condition characterized by motor impairment, increased spasticity, and significant functional limitations in daily activities. Spasticity is one of the most common secondary complications after upper motor neuron lesions and can negatively affect rehabilitation outcomes, gait ability, and functional independence.\n\nThis randomized controlled study aims to investigate the effects of Functional Electrical Stimulation (FES) applied to the quadriceps muscle in individuals with paraplegia. Participants will be randomly assigned to either a control group receiving conventional neurorehabilitation or an intervention group receiving additional FES treatment.\n\nThe primary outcomes include changes in spasticity level, quadriceps muscle strength, and functional mobility. Spasticity will be assessed using the Modified Ashworth Scale (MAS), muscle strength will be evaluated with Manual Muscle Testing (MMT), and functional mobility will be measured using the Spinal Cord Independence Measure (SCIM), Timed Up and Go Test (TUG), and 6-Minute Walk Test (6MWT).\n\nThe intervention period will last 8 weeks, with standardized rehabilitation programs applied to both groups. The FES group will additionally receive quadriceps stimulation with specific neuromuscular electrical stimulation parameters.\n\nThe findings of this study are expected to provide evidence regarding the effectiveness of FES as an adjunct to conventional rehabilitation in improving motor function and functional independence in individuals with paraplegia.",[29,290,427,428],"Spasticity","Neurorehabilitation",[29,430,428,427,290],"Paraplegia Rehabilitation","2026-05-15",{"date":433,"type":34},"2026-05-19",{"date":435,"type":22},"2026-05-10",{"date":437,"type":22},"2026-07-10",{"name":439,"class":65},"Istanbul Medipol University Hospital",{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":447,"targetDuration":4,"studyType":23,"phases":448,"briefSummary":450,"conditions":451,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":4},"100639554","phase-1-olfactory-cell-transplantation-and-intensive-rehabilitation-to-repair-chronic-spinal-cord-injury-100639554","NCT07596563","Olfactory Cell Transplantation and Intensive Rehabilitation to Repair Chronic Spinal Cord Injury","Safety, Feasibility, Efficacy of Olfactory Cell Transplantation Therapy Combined With Intensive Exercise Rehabilitation to Repair Chronic Traumatic Spinal Cord Injury.","Inclusion\u002Fexclusion criteria for participants have been determined in consultation with medical and rehabilitation specialists including a clinician with lived experience of SCI.\n\nInclusion Criteria\n\nParticipants are eligible to be included in the trial only if all the following criteria apply:\n\n1. Have sustained an acquired spinal cord injury a minimum of 4 months prior to consent and have completed their primary rehabilitation;\n2. Have a stable neurological level and functional ability of more than two months in duration;\n3. Are over 18 years and able to give informed consent;\n4. Are AIS A, B or low functioning C (more than 75% of key muscles have a power grade \\\u003C3) as per the International Standards for Neurological Classification of spinal cord injury, and documented by an ISNCSCI\u002FASIA exam performed by a qualified practitioner within the last six months;\n5. Have a thoracic injury or lower cervical (C5-C8) injury;\n6. Are able and willing to attend an exercise program five times per week for the duration of the priming rehabilitation program, with allowance for two weeks recreational leave;\n7. Are able and willing to attend an exercise program five times per week for at least 12 weeks of the regenerative rehabilitation program and then at least three days per week for the remaining 20 weeks, with allowance for four weeks recreational leave;\n8. Are considered by their general practitioner or specialist medical consultant to be fit to receive the cell transplantation and undertake the exercise program (documented approval by general practitioner required).\n\nExclusion Criteria\n\nParticipants are excluded from the trial if any of the following criteria apply:\n\n1. Have a high cervical (C1-C4) injury (excluded due to respiratory risk);\n2. Have significant concomitant central nervous system, peripheral nervous system or musculoskeletal system injuries or disorders limiting their ability to exercise;\n3. Have had recent major trauma or surgery within the last 4 months;\n4. Have an existing stage 3 or 4 pressure ulcer according to the National Pressure Ulcer Advisory Panel classification;\n5. Have endocrinopathy or metabolic disorders of the bone that lead to increased risk of injury from the intense long-term exercise therapy, including but not limited to pathological fractures, Paget's disease, lytic or renal bone disease, and senile osteoporosis;\n6. Have a medical history of exposure to medication(s) known to adversely affect mineral or bone metabolism;\n7. Have significant impairment or disability, including physical, neurological or psychological impairments, in addition to the spinal cord injury;\n8. Have a history of long bone fracture incompletely healed;\n9. Have extensive fixed contractures in the upper or lower limbs;\n10. Have severe spasticity that interferes with ability to exercise;\n11. Have uncontrolled neuropathic pain;\n12. Have autonomic dysreflexia without a management plan;\n13. Have a known allergic sensitivity to antibiotics used in the nerve bridge production process;\n14. Do not have adequate transport options to attend the rehabilitation sessions or the assessments;\n15. Are unable to attend the pre-intervention assessments and the follow-up assessments;\n16. Have any contraindications to FES, MRI, X-ray and other study procedures, such as a cardiac pacemaker, epilepsy, lower limb fracture or pregnancy;\n17. Have any other serious medical condition including but not limited to malignancies, auto-immune disorders (requiring continuous pharmaceutical management), psychiatric, behavioural or drug dependency problems, which are likely to influence the participant's ability to cooperate or, in the opinion of the trial investigator, would prevent adherence to the protocol;\n18. Have symptomatic, radiologically demonstrated, or provocatively demonstrated ischaemic heart disease;\n19. Have current thromboembolic disease;\n20. Are using illicit drugs;\n21. Are participating in other clinical trials (including medication, therapeutic interventions and alternative therapies).\n22. Are unable to tolerate expected exercise load.\n23. Are unable to comply with the assessment regime (such as having claustrophobia which prevents MRI procedures being conducted);\n24. Are unable to demonstrate that they have adequate social\u002Ffamily\u002Fcarer support at home to enable their participation throughout the trial.\n25. Evidence of an active infection, confirmed by testing, of a type that would pose an unacceptable risk for the viability of the nasal biopsy, the cell production, or the nerve bridge production.",{"count":368,"type":22},[449],"PHASE1","This is a randomised, blinded and controlled Phase I trial to measure the safety, feasibility and efficacy of a combined cell transplantation and intensive rehabilitation intervention to treat spinal cord injury. The trial aims to examine whether transplantation of olfactory cell nerve bridges combined with intensive rehabilitation is safe and feasible for people living with chronic spinal cord injury in Australia, and whether the intervention improves structural integrity of the spinal cord, functional recovery, overall health, and social wellbeing.\n\nFor the olfactory cell nerve bridge transplant, cells from inside the patient's own nose will be purified and engrafted as 3D cellular nerve bridges. Participants will receive a dose that is dependent on the size of the accessible space within the injury site of the spinal cord with up to 60 million cells being engrafted. The surgery for the transplantation will be performed by a neurosurgeon in which the spinal cord will be exposed to enable the nerve bridges to be placed into the injury site. The duration of the procedure will be 3-4 hours. Surgical notes will be used to monitor adherence to the protocol.\n\nFor intensive exercise rehabilitation, the intervention will be supervised and provided by physiotherapists and exercise physiologists at a for-purpose neurorehabilitation facility. The mode of administration will be one-on-one sessions. The 12- and 32-week rehabilitation programs will consist of up to 3 hours per day at the rehabilitation service providers, for 5 days per week. Participants will attend the provider that is within their geographical area. Over each week, sessions will involve a range and mix of activities which could include, but are not limited to, standing, gait training, upper limb strength, trunk stability\u002Fcore strength, and aerobic training. Throughout the trial, logs of exercise activities will be completed by the participants and staff at the neurorehabilitation gyms. Rehabilitation will start from day 1 of the priming rehabilitation (PR) program and go for 12 weeks, then surgery and cell transplantation will occur at week 1 of the cell transplantation surgery and recover program which is 2 weeks post conclusion of Priming Rehabilitation (PR), followed by 5 weeks of recovery.\n\nRehabilitation is for 32 weeks starting 6 weeks post transplant surgery. Regenerative rehabilitation program is from weeks 1-32 of the regenerative rehabilitation (RR) program.\n\nIf nerve bridge production fails for whatever reason in the weeks prior to surgery, this will start an extension\u002Fcontingency\u002Falternative timeline, where a new nasal biopsy will need to be taken from the participant (along with accompanying tests). The cells will be grown up over the next 4 weeks with an additional week of nerve bridge production, while the participant engages in a further five weeks of priming rehabilitation.",[29,452,453],"Neurological Conditions","Rehabilitation Exercise","2026-05-12",{"date":433,"type":34},{"date":457,"type":22},"2026-05-01",{"date":459,"type":22},"2031-08-01",{"name":461,"class":65},"Dr Brent McMonagle",{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":4,"eligibilityCriteria":468,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":23,"phases":471,"briefSummary":472,"conditions":473,"keywords":476,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":42},"100501163","calcitonin-therapy-on-incidence-and-severity-of-neuropathic-pain-after-spinal-cord-injury-100501163","NCT05805683","Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury","Effect of Early Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury","Inclusion Criteria:\n\n* Patients aged ≥18 years, with spinal cord injury at any level and any degree of completeness in the early stage of trauma.\n\nExclusion Criteria:\n\n* Intake of anticonvulsants medications.\n* Evidence of neuropathic pain.\n* Evidence of previous allergic reaction to calcitonin.\n* Patients with renal, hepatic and cardiac dysfunction or neurological disorders .\n* brain damage or major trauma to extremities or abdomen.",{"count":470,"type":22},126,[53],"This prospective randomized double blinded study will be conducted to evaluate the effect of early pharmacologic intervention with calcitonin on the incidence or the severity of neuropathic pain after spinal cord injury",[474,475,29],"Calcitonin","Neuropathic Pain",[474,477,288],"Neuropathic pain","2026-05-11",{"date":480,"type":34},"2026-05-14",{"date":482,"type":34},"2023-05-01",{"date":484,"type":22},"2028-05-01",{"name":486,"class":65},"Tanta University",{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":200,"enrollmentInfo":494,"targetDuration":4,"studyType":23,"phases":496,"briefSummary":497,"conditions":498,"keywords":501,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":509,"completionDateStruct":510,"leadSponsor":512,"locationsCount":42},"100637196","phase-1-fes-cycling-with-bfr-in-the-spinal-cord-injury-population-100637196","NCT07588503","FES Cycling With BFR in the Spinal Cord Injury Population","Assessing the Safety and Feasibility of Functional Electrical Stimulation Cycling Coupled With Blood Flow Restriction in a Spinal Cord Injury Population","Inclusion Criteria:\n\n* Adult (≥ 18 to ≤ 75yrs)\n* Male or female\n* Chronic Injury (\\>1yr)\n* Diagnosis of SCI at levels between C5 to T10 (AIS A-D) with traumatic or non-traumatic etiology.\n* ≥3 Cardiometabolic risk parameters\n\nExclusion Criteria:\n\n* A prior or current history of venous thromboembolism\n* Pressure injury of the pelvis, mid to upper thigh region, or foot\n* Managing a lower limb fracture\n* Any history of embolic stroke\n* Myocardial infarction\n* Current untreated hypertension\n* Language, psychiatric, cognitive, or communicative disability (e.g., traumatic brain injury) that compromises the participant's autonomy to voluntarily join the study, follow its instructions and\u002For operate the device.\n* Current alcohol or street drug use disorder.\n* Current use of an anticoagulant medication.\n* Frequent episodes of autonomic dysreflexia unresponsive to therapy (e.g., 3-5 times a week).\n* Unresolved deep vein thromboembolism (VTE) in the past six months.\n* Severe spasticity preventing the necessary range of motion for cycling.\n* Active implantable medical device (e.g., pacemaker, ITB pump).\n* Inability to provide informed consent.\n* Severe active concurrent medical conditions (e.g., skin or respiratory infections, lung, pressure sores).\n* Unstable spine or unhealed limbs or pelvic fractures.\n* Active heterotopic ossification interfering with the lower extremity range of motion.",{"count":495,"type":22},6,[449],"Cardiometabolic Disease (CMD) is the silent killer within the spinal cord injury\u002Fdisease (SCI\u002FD) population. Many SCI\u002FD patients' initial CMD presentation is with a heart attack, stroke, or sudden cardiac death, highlighting the need for interventions to reduce CMD risk. CMD contributes to 46% of deaths, with 30-50% of the SCI\u002FD population living with undiagnosed CMD. Treating CMD risk is more challenging in the SCI\u002FD population due to prolonged inactivity, inability to exercise, and excessive caloric intake to expenditure ratio. Identifying accessible and inclusive strategies to combat CMD risk in the SCI\u002FD population is a compelling and urgent health priority.\n\nBlood flow restriction (BFR) exercise involves applying inflatable cuffs to the proximal end of an individual's limbs. Changes to the amount of blood flowing into and out of the limb lead to a low oxygen environment within the limb, shifting the way the muscles can produce the energy required to function, increasing the benefits of low- and moderate-intensity exercise. Coupling BFR with Functional electrical stimulation cycling (FES-cycling), a commonly used rehabilitation tool within the SCI population, could improve FES-cycling's short- and long-term benefits without reducing the accessibility and inclusiveness of long-term exercise prescription. Although preliminary BFR research in the SCI\u002FD has identified positive muscular improvements, whether FES-cycling coupled with BFR can be safely prescribed or feasibly implemented long-term within the SCI\u002FD population is unknown.\n\nThe proposed project aims to determine the safety and feasibility of FES-cycling coupled with BFR for 20 minutes of moderate-intensity exercise among adults with chronic spinal cord injury\u002Fdisease (SCI\u002FD). The research team aims to implement pre-test, eight exercise sessions, and post-test across 6-weeks. Criteria for success include no adverse or severe adverse events not alleviated by ceasing exercise (safety), a 1 to 8 ratio of participants screened to participants eligible (recruitment success), and participants successfully completing all exercise sessions (participant retention).",[29,499,500],"Cardio Vascular Disease","Metabolic Diseases, Type 2 Diabetes, Cardiovascular Disease",[502,503,29,504,505,506],"Safety","Feasability","Blood Flow Restricted Aerobic Exercise","Functional Electrical Stimulation","Cycling","2026-05-08",{"date":480,"type":34},{"date":244,"type":22},{"date":511,"type":22},"2027-09-30",{"name":513,"class":65},"Dr. B. Catharine. Craven",{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":521,"targetDuration":4,"studyType":23,"phases":523,"briefSummary":524,"conditions":525,"keywords":526,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":42},"100637499","transcutaneous-auricular-vagus-nerve-stimulation-as-a-treatment-for-neuropathic-pain-following-spinal-cord-injury-100637499","NCT07588711","Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Neuropathic Pain Following Spinal Cord Injury","Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) as an Anti-inflammatory Strategy for the Treatment of Neuropathic Pain Following Spinal Cord Injury","Inclusion Criteria:\n\n* SCI of any level or severity\n* 18 years of age or older\n* current neuropathic pain\n* on no medications or on a stable prescribed dose (no change in prior 6-weeks) of anti-inflammatory, pain medications and\u002For depression medications\n\nExclusion Criteria:\n\n* Prone to autonomic dysreflexia\n* presence of cardiovascular disease\n* pacemaker or other implanted electrical device\n* cerebral shunts\n* epilepsy\n* pregnant or attempting to become pregnant\n* current wound\u002Finfection\n* unstable dose of prescribed anti-inflammatory, depression, or pain medications within past 6-weeks.",{"count":522,"type":22},32,[53],"This pilot randomized, double-blind, sham-controlled clinical investigation will evaluate the feasibility and safety of a 30-day home-based transcutaneous auricular vagus nerve stimulation (taVNS) intervention in adults with spinal cord injury (SCI) and neuropathic pain. Participants will be randomized to receive either active taVNS targeting the auricular branch of the vagus nerve or sham taVNS delivered to the earlobe. Primary outcomes include feasibility, safety, adherence, acceptability, and blinding success. Exploratory outcomes include changes in neuropathic pain, systemic inflammatory biomarkers, vagal tone assessed via heart rate variability, and quality of life.",[29,475],[527,528,108,529,530],"vagus nerve stimulation","inflammation","neuropathic pain","taVNS","2026-05-07",{"date":431,"type":34},{"date":534,"type":22},"2026-10-01",{"date":536,"type":22},"2028-08-30",{"name":538,"class":65},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":23,"phases":548,"briefSummary":549,"conditions":550,"keywords":551,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":557,"completionDateStruct":558,"leadSponsor":560,"locationsCount":42},"100622199","xo-motion-r-exoskeleton-in-sci-adoption-study-100622199","NCT07380516","Xo-Motion R Exoskeleton in SCI-Adoption Study","Adoption of the Xo-Motion R in the Subacute and Chronic SCI Populations at the Glenrose Rehabilitation Hospital","Inclusion Criteria:\n\n* SCI (AIS C or D in inpatient setting, AIS B-D in outpatient setting; inclusive of cervical injuries)\n* inpatients who are preambulatory with predicted probability of walking independently 1year after injury \\>50% (Hicks et al., 2017)\n* outpatients with a functional goal of improved locomotion where the XoMotion is clinically suited to support the achievement of their functional goals\n\nExclusion Criteria:\n\n* SCI AIS A",{"count":547,"type":22},16,[53],"After spinal cord injury (SCI), many people lose their ability to walk and do not have access to equipment and assistance that could help them regain functional abilities. Furthermore, many who have the potential to regain function are further hindered by a loss of function in their upper body that limits their ability to use a walker or crutches, thus eliminating options for mobility.\n\nThis study seeks to determine the safety and feasibility of the XoMotion-R, a self-balancing exoskeleton that allows people with American Spinal Injury Association Impairment Scale (AIS) rating of B-D SCI to walk hands-free in inpatient and outpatient settings. This study will examine how use of the XoMotion-R affects functional outcomes and identify setting-specific barriers and facilitators to clinical adoption.\n\nThis single-arm feasibility study will recruit 8 SCI inpatients and 8 SCI outpatients whose goal is to improve their walking and incorporate the XoMotion-R into their rehabilitation sessions. Participants will work on a variety of gait tasks tailored to their functional level. The goal is to determine whether early robotic gait training can improve functional outcomes and decrease length of stay, secondary complications, and long-term disability burden.",[29],[552,553,554,289],"exoskeleton","rehabilitation","locomotion","2026-05-05",{"date":531,"type":34},{"date":166,"type":22},{"date":559,"type":22},"2026-09",{"name":561,"class":65},"University of Alberta",{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":571,"conditions":572,"keywords":574,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":577,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":581,"locationsCount":42},"100600038","studying-rehabilitation-treatments-using-video-to-improve-recovery-for-adults-with-physical-disabilities-100600038","NCT07092293","Studying Rehabilitation Treatments Using Video to Improve Recovery for Adults With Physical Disabilities","Using the Rehabilitation Treatment Specification System (RTSS) to Maximize Rehabilitation Research Impact: A Video-Based Observational Study","Occupational Therapy Inclusion Criteria:\n\n* Must be a licensed OT practitioner (occupational therapist or occupational therapy assistant),\n* The OT practitioner must treat at least one adult stroke or spinal cord injury patient with UE sensorimotor impairment per month\n* The OT practitioner must be willing to be video recorded while treating their enrolled stroke or SCI patients.\n\nStroke Patients Inclusion Criteria:\n\n* Must have a medical diagnosis of ischemic or hemorrhagic stroke\n* Must be ≥ 18 years old\n* Must have at least one OT goal related to UE hemiparesis\n* Must have at least one remaining OT treatment session after enrollment\n* The patient's OT must be enrolled in the study.\n\nSpinal Cord Injury (SCI) Patients Inclusion Criteria:\n\n* Must have a medical diagnosis of cervical spinal cord injury\n* Must be ≥ 18 years old\n* Must have at least one OT goal related to UE sensorimotor impairment\n* Must have at least one remaining OT treatment session after enrollment\n* The patient's OT must be enrolled in the study.",{"count":570,"type":22},90,"This study aims to better understand how occupational therapists provide rehabilitation for adults recovering from stroke or spinal cord injury (SCI), with a focus on improving arm and hand function. Using video recordings of real outpatient therapy sessions, researchers will identify the key elements of treatment, such as the types of activities, the therapist's techniques, and how patients respond. The study will use the Rehabilitation Treatment Specification System (RTSS), a framework designed to clearly describe rehabilitation methods. By analyzing these sessions, the research team will develop a practical toolkit to help therapists and researchers deliver and study more effective rehabilitation treatments in the future.",[346,29,573],"Occupational Therapy",[575,576,108],"occupational therapy","stroke",{"date":531,"type":34},{"date":579,"type":34},"2025-02-11",{"date":62,"type":22},{"name":170,"class":65},{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":586,"acronym":4,"eligibilityCriteria":587,"healthyVolunteers":12,"sex":17,"minAge":588,"maxAge":4,"enrollmentInfo":589,"targetDuration":591,"studyType":75,"phases":4,"briefSummary":592,"conditions":593,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":594,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":601},"100580592","the-international-spinal-cord-injury-blood-biomarker-longitudinal-evaluation-i-scribble-study-100580592","NCT06839300","The International Spinal Cord Injury Blood Biomarker Longitudinal Evaluation (I-SCRIBBLE) Study","Inclusion Criteria:\n\n* Age ≥ 19 years\n* Blunt (non-penetrating) traumatic SCI\n* Baseline neurologic impairment deemed \"complete\" (AIS grade A) or \"incomplete\" (AIS grade B, C, or D) based on clinical history\u002Fexamination and\u002For diagnostic imaging\n* Bony spinal level involvement between C0 and L1, inclusive\n* Ability to have initial blood sample drawn within 24 hours of injury\n* Treated either surgically or non-surgically\n* Ability to provide informed consent according to the IRB\u002FEC defined and approved procedures\n\nInclusion criteria for non-spinal cord injury spinal trauma control participants:\n\n* Age ≥ 19 years\n* Traumatic spinal fracture and\u002For dislocation between C0 and L1 (inclusive) without SCI\n* Treated either surgically or nonsurgically\n* Ability to have initial blood sample drawn within 24 hours of injury\n* Ability to provide informed consent according to the IRB\u002FEC defined and approved procedures\n\nExclusion Criteria:\n\n* Penetrating SCI (eg, gunshot, stab)\n* Previous SCI\n* Isolated spinal injury below L1\n* Isolated radiculopathy without fracture\n* Isolated cauda equina injury\n* Patients with known diagnosis of multiple sclerosis\n* Preexisting thromboembolic disease or coagulopathy (disorders related to blood clotting), such as hemophilia or von Willebrand disease\n* Patients who in the investigator's opinion will not be compliant with the study procedures and patients who have any other conditions\u002Finjuries that in the investigator's opinion would render the study procedures dangerous","19 Years",{"count":590,"type":22},260,"12 Months","To determine the accuracy of serum NF-L and GFAP levels (ie the biomarkers) at different time points postinjury for predicting the severity of neurologic impairment at 6 months postinjury as either motor complete (AIS grade A\u002FB) or motor incomplete (AIS grade C\u002FD) a group of patients who suffer traumatic spinal fracture and\u002For dislocation of the spinal column but without neurologic injury will be enrolled as non-SCI spine trauma control participants.",[29],{"date":555,"type":34},{"date":596,"type":34},"2026-02-09",{"date":598,"type":22},"2029-12-01",{"name":600,"class":65},"AO Foundation, AO Spine",8,{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":607,"acronym":4,"eligibilityCriteria":608,"healthyVolunteers":12,"sex":17,"minAge":588,"maxAge":4,"enrollmentInfo":609,"targetDuration":4,"studyType":23,"phases":610,"briefSummary":611,"conditions":612,"keywords":613,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":618,"startDateStruct":619,"completionDateStruct":620,"leadSponsor":622,"locationsCount":42},"100570326","exploring-the-benefits-of-pelvic-floor-muscle-training-on-bladder-bowel-and-sexual-function-in-people-with-spinal-cord-injury-100570326","NCT06705790","Exploring the Benefits of Pelvic Floor Muscle Training on Bladder, Bowel, and Sexual Function in People With Spinal Cord Injury","Exploring the Feasibility and Urogenital Benefits of Pelvic Floor Muscle Training in Individuals With Motor-incomplete Spinal Cord Injury","Inclusion Criteria:\n\n* Are at least 19 years of age.\n* Have a non-progressive, motor-incomplete spinal cord injury that is at or above the T12 neurological level at least 12 months ago.\n* Have symptoms of bladder, bowel, and\u002For sexual dysfunction that are caused by your spinal cord injury.\n* Have stable management of spinal cord related secondary health concerns (e.g., spasticity, neuropathic pain).\n* Are able to speak and understand English.\n\nExclusion Criteria:\n\n* Are currently pregnant, have been pregnant within the past 6 months, or are planning to become pregnant in the next 6 months.\n* Have had urogenital surgery within the past 12 months.\n* Have received Botox bladder injections within the past 4 weeks, or anticipate receiving an injection in the next 6 months.\n* Have presence of severe medical issue that in the investigator's judgement would adversely affect the participant's participation in the study. Examples include, but are not limited to pressure sores, cardiovascular disease, and unmanaged diabetes.\n* Have any permanent metal fixtures in their head (excluding dental fillings), or pacemakers, stimulators, or implanted medication pumps.\n* Have a history of seizures, are taking medications that lower the seizure threshold, or experience recurring headaches.\n* Have a condition for which exercise is contraindicated.",{"count":368,"type":22},[53],"The goal of this trial is to learn about the feasibility and benefits of delivering a pelvic floor muscle training program to people with motor-incomplete spinal cord injury. The main questions it aims to answer are:\n\n1. To evaluate the feasibility of delivering a pelvic floor muscle training program to people with spinal cord injury. The investigators will examine recruitment rate, compliance and adherence to the intervention and other study protocols, adverse events, and participant perspectives of the study protocols.\n2. To explore the potential effectiveness of pelvic floor muscle training on pelvic floor, bladder, bowel, and sexual function.\n\nParticipants will be asked to complete a pelvic floor muscle training program for 3 months. At the beginning, middle, and end of the program, researchers will conduct a series of tests to determine the feasibility and potential effectiveness of this program.",[29],[29,614,615,616,617],"Pelvic Floor Muscle Training","Bladder","Bowel","Sexual Health",{"date":507,"type":34},{"date":60,"type":22},{"date":621,"type":22},"2028-03-31",{"name":332,"class":65},{"id":624,"slug":625,"hasResults":12,"nctId":626,"briefTitle":627,"officialTitle":628,"acronym":4,"eligibilityCriteria":629,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":630,"targetDuration":4,"studyType":23,"phases":631,"briefSummary":632,"conditions":633,"keywords":635,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":642,"lastUpdatePostDateStruct":643,"startDateStruct":644,"completionDateStruct":646,"leadSponsor":648,"locationsCount":42},"100624291","clinical-outcome-assessment-for-at--bci-100624291","NCT07407725","Clinical Outcome Assessment for AT & BCI","Development of a Clinical Outcome Assessment for Assistive Technologies and Brain-Computer-Interfaces","Enrollment will involve three different cohorts, namely a cohort of healthy participant, a cohort of ALS\u002FSCI participant who underwent the implant of an invasive BCI device, and a cohort of ALS\u002FSCI participants without any implanted BCI device.\n\nBelow are listed the inclusion and exclusion criteria for each diagnostic group.\n\nSpinal Cord Injury (SCI):\n\nInclusion Criteria:\n\n* Age at or above 18 years old;\n* Diagnosis of spinal cord injury, at the level of T1 or above levels (between C1 and T1);\n* Ability to communicate independently or with a support device, or with a legal representative;\n* Ability to participate in a study session for about 3 hours (e.g., endurance, fatigue), which may include breaks as needed.\n\nExclusion Criteria:\n\n* Participation in another trial that would conflict with the current study or clinical endpoint interference may occur.\n\nAmyotrophic Lateral Sclerosis (ALS):\n\nInclusion criteria:\n\n* Age at or above 18 years old;\n* Diagnosis of amyotrophic lateral sclerosis;\n* Ability to communicate independently, with a support device, or with a legal representative;\n* Ability to participate in a study session for about 3 hours (e.g., endurance, fatigue), which may include breaks as needed.\n\nExclusion criteria:\n\n● Participation in another trial that would conflict with the current study or clinical endpoint interference may occur.\n\nHealthy Controls:\n\nInclusion criteria:\n\n* Age at or above 18 years old;\n* No history of neurological or psychiatric disorders;\n* Ability to provide written informed consent;\n* Ability to participate in a study session for about 3 hours (e.g., endurance, fatigue), which may include breaks as needed.\n\nExclusion criteria:\n\n* Participation in another trial that would conflict with the current study or clinical endpoint interference may occur;\n* Cognitive, visual, or auditory deficits that would interfere with study participation;\n* Current or prior diagnosis or condition that could confound study assessments.",{"count":227,"type":22},[53],"Many individuals with severe motor impairments rely on Assistive Technologies (ATs) or Brain-Computer Interfaces (BCIs) to interact with digital devices such as their computers. Clinicians and researchers currently lack a common framework to objectively quantify how much a given AT or BCI improves real-world function or to compare across tools. This project seeks to address this gap by developing a standardized method to objectively assess or compare the functional benefit of these tools on digital independence, i.e., the ability to independently operate computers, phones, and other digital systems, by creating a unique Digital Assessment Interface (DAI).\n\nThis assessment will be a simulation of online and digital activities that prior work has determined is important to functional daily living in the digital domain. Participants will complete this assessment with various ATs and BCIs, and these scores will be used to create an index, which will be comprised of performance outcomes, clinician-reported outcomes, and patient-reported outcomes.\n\nThe tool aims to quantify and compare digital task performance across devices and user populations. The primary objective of this study is to develop an index. The index will quantify functional performance of individuals using various ATs and BCIs. The secondary objectives are to extensively evaluate the psychometric properties of the index, such as the validity, responsiveness, reliability, and floor\u002Fceiling effects both globally and across different devices and impairment levels, ensuring that it can reliably measure the impact of an AT or BCI on a user's ability to independently operate digital systems; and to characterize the familiarization and use of specific BCI and AT systems with reference to a normative healthy control population.",[29,634],"ALS (Amyotrophic Lateral Sclerosis)",[636,637,638,639,640,641],"iBCI","Brain Computer Interface","Assistive Technology","Clinical Outcome Assessment","dADL","digital activities of daily living","2026-04-29",{"date":555,"type":34},{"date":645,"type":34},"2026-01-08",{"date":647,"type":22},"2027-06",{"name":649,"class":65},"Shirley Ryan AbilityLab"]